Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions

Journal of Cutaneous Pathology

Volumn 34, Issue 6, 2007, Pages 448-455

  Indsto, James O ^a   Kumar, Swapna ^a   Wang, Lixiang ^b   Crotty, Kerry A ^b   Arbuckle, Susan M ^c   Mann, Graham J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN CDKN2A; PROTEIN DERIVATIVE; RAS PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CELL PROLIFERATION; CHROMOSOME 10Q; CHROMOSOME 9P; CODON; CONTROLLED STUDY; DELETION MUTANT; FEMALE; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; GERM LINE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; JUVENILE MELANOMA; MALE; MELANOMA; MICROSATELLITE INSTABILITY; MUTATIONAL ANALYSIS; NEVUS; ONCOGENE H RAS; ONCOGENE N RAS; PRESCHOOL CHILD; PREVALENCE; SIGNAL TRANSDUCTION;

ADOLESCENT; AUSTRALIA; CELL LINE, TUMOR; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MALE; MELANOMA; MUTATION; NEVUS, EPITHELIOID AND SPINDLE CELL; PREVALENCE; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 34249050450     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2006.00646.x     Document Type: Article

References (52)

1. Clark WH Jr., Guerry D, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984 15:1147.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990 61:759.
3. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol 2003 139:1620.
4. Whiteman DC, Watt P, Purdie DM, Hughes MC., Hayward NK, Green AC, Parsons PG. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma, p53 expression and risk factors for cutaneous melanoma: a case-control study. J Natl Cancer Inst 2003 95:806.
5. Crotty KA, Scolyer RA, Li L, Palmer AA, Wang L, McCarthy SW. Spitz naevus versus Spitzoid melanoma: when and how can they be distinguished? Pathology 2002 34:6.
6. Riley PA. Naevogenesis: a hypothesis concerning the control of proliferation of melanocytes with special reference to the growth of intradermal naevi. Dermatology 1997 194:201.
7. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003 33:19.
8. Robinson WA, Elefanty A, Harrison-Smith M, Markham N, Norris D. Human acquired naevi are clonal. Melanoma Res 1998 8:499.
9. Indsto JO, Cachia AR, Kefford RF, Mann GJ. X inactivation, DNA deletion, and microsatellite instability in common acquired melanocytic nevi. Clin Cancer Res 2001 7:4054.
10. Hui P, Perkins A, Glusac E. Assessment of clonality in melanocytic nevi. J Cutan Pathol 2001 28:140.
11. Maldonado JL, Timmerman L, Fridlyand TJ, Bastian B Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the Map-kinase pathway. Am J Pathol 2004 164:1783.
12. van Elsas A, van der Flier S, Kruse KM, et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996 149:883.
13. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J. Screening of NRAS codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002 8:3468.
14. van 't Veer LJ, Burgering BM, Versteeg R, et al. NRAS mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989 9:3114.
15. Kumar R, Angelini S, Hemminki K. Activating BRAF and NRAS mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 2003 22:9217.
16. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004 122:337.
17. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002 417:949.
18. Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A, Pringle JH. High Braf mutation frequency does not characterize all melanocytic tumor types. Int J Cancer 2004 111:705.
19. Mihic-Probst D, Perren A, Schmid S, Sarmaslani P, Komminoth P, Heitz, PU. Absence of Braf gene mutations differentiates Spitz nevi from malignant melanoma. Anticancer Res 2004 24:2415.
20. Palmedo G, Hantschke M, Rutten A, et al. The T1796A mutation of the BRAF gene is absent in Spitz nevi. J Cutan Pathol 2004 31:266.
21. Gill M, Cohen J, Renwick N, Mones JM, Silvers DN, Celebi JT. Genetic similarities between Spitz nevus and spitzoid melanoma in children. Cancer 2004 101:2636.
22. Gill M, Renwick N, Silvers DN, Celebi JT. Lack of BRAF mutations in Spitz nevi. J Invest Dermatol 2004 122:1325.
23. van Dijk MC, Bernsen MR, Ruiter DJ. Analysis of mutations in B-Raf, N-Ras, and H-Ras genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol 2005 29:1145.
24. Turner DJ, Zirvi MA, Barany F, Elenitsas R, Seykora J. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. J Cutan Pathol 2005 32:334.
25. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 2000 157:967.
26. Holland EA, Beaton SC, Edwards BG, Kefford RF, Mann GJ. Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma. Oncogene 1994 9:1361.
27. Walker GJ, Palmer JM, Walters MK, Hayward NK. A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer 1995 12:134.
28. Herbst RA, Weiss J, Ehnis A, Cavenee WK, Arden KC. Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res 1994 54:3111.
29. Indsto JO, Holland EA, Kefford RF, Mann GJ. 10q deletions in metastatic cutaneous melanoma. Cancer Genet Cytogenet 1998 100:68.
30. Healy E, Belgaid C, Takata M, et al. Prognostic significance of allelic losses in primary melanoma. Oncogene 1998 16:2213.
31. Isshiki K, Seng BA, Eldwer DE, Guerry D, Linnenbach A. Chromosome 10 allelic loss in malignant melanoma. Genes Chromosomes Cancer 1993 8:178.
32. Walker GJ, Palmer JM, Walters MK, Nancarrow DJ, Parsons PG, Hayward NK. Refined localization of the melanoma (Mlm) gene on chromosome 9p by analysis of allelic deletions. Oncogene 1994 9:819.
33. Bogdan I, Burg G, Boni R. Spitz nevi display allelic deletions. Arch Dermatol 2001 137:1417.
34. Lang J, Boxer M, MacKie R. Absence of exon 15 BRAF germline mutations in familial melanoma. Hum Mutat 2003 21:327.
35. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual, 2nd ed. New York:Cold Spring Harbour Laboratory Press, 1989.
36. Harland M, Holland EA, Ghiorzo P, et al. Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes Cancer 2000 28:45.
37. Giambernardi TA, Rodeck U, Klebe RJ. Bovine serum albumin reverses inhibition of RT-PCR by melanin. Biotechniques 1998 25:564.
38. Kroiss MM, Vogt TM, Schlegel J, Landthaler M, Stolz W. Microsatellite instability in malignant melanomas. Acta Derm Venereol 2001 81:242.
39. Peris K, Keller G, Chimenti S, Amantea A, Kerl H, Hofler H. Microsatellite instability and loss of heterozygosity in melanoma. J Invest Dermatol 1995 105:625.
40. Talwalkar VR, Scheiner M, Hedges LK, Butler MG, Schwartz HS. Microsatellite instability in malignant melanoma. Cancer Genet Cytogenet 1998 104:111.
41. Hussein MR, Wood, GS. Microsatellite instability in human melanocytic skin tumors: an incidental finding or a pathogenetic mechanism? J Cutan Pathol 2002 29:1.
42. Barnhill RL, Flotte TJ, Fleischli M, Perez-Atayde A. Cutaneous melanoma and atypical Spitz tumors in childhood. Cancer 1995 76:1833.
43. Omholt K, Platz A, Kanter L. Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003 9:6483.
44. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003 121:1160.
45. Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004 122:342.
46. Harvell JD, Meehan SA, LeBoit PE. Spitz's nevi with halo reaction: a histopathological study of 17 cases. J Cutan Pathol 1997 24:611.
47. Rivers JK. Is there more than one road to melanoma? Lancet 2004 363:728.
48. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003 95:1878.
49. Healy E, Belgaid CE, Takata M, et al. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res 1996 56:589.
50. Rubben A, Bogdan I, Grussendorf-Conen EI, Burg G, Boni R. Loss of heterozygosity and microsatellite instability in acquired melanocytic nevi: towards a molecular definition of the dysplastic nevus. Recent Results Cancer Res 2002 160:100.
51. Weedon D, Little JH. Spindle and epithelioid cell nevi in children and adults. A review of 211 cases of the Spitz nevus. Cancer 1977 40:217.
52. Ko CB, Walton S, Wyatt EH, Bury HP. Spitz nevus. Int J Dermatol 1993 32:354.